v3.26.3
Product Revenue
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Product Revenue Product Revenue
The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA® and TEVIMBRA® in the U.S., China, EU, and other regions; XGEVA®, BLINCYTO® and KYPROLIS® in China under a license from Amgen; BAITUOWEI® in China under a license from Luye Pharma; and POBEVCY® in China under a license from Bio-Thera.
The table below presents the Company’s net product revenue for the three and nine months ended September 30, 2026 and 2025:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
$$$$
Product revenue – gross2,436,062 1,770,689 6,535,151 4,828,593 
Less: rebates and sales returns(581,005)(375,676)(1,512,971)(1,022,974)
Product revenue – net1,855,057 1,395,013 5,022,180 3,805,619 
The following table disaggregates net product revenue by product for the three and nine months ended September 30, 2026 and 2025:
Three Months EndedNine Months Ended
September 30,September 30,
2026202520262025
$$$$
BRUKINSA®
1,390,936 1,040,691 3,733,419 2,782,195 
TEVIMBRA®
243,282 190,623 678,038 555,311 
XGEVA®
105,482 84,243 299,901 235,984 
BLINCYTO®
38,869 30,476 109,441 79,969 
KYPROLIS®
13,900 18,369 46,018 57,513 
BAITUOWEI®
22,111 11,243 54,110 25,920 
POBEVCY®
10,717 10,499 32,477 35,486 
Other29,760 8,869 68,776 33,241 
Total product revenue – net1,855,057 1,395,013 5,022,180 3,805,619 
The following table presents the roll-forward of accrued revenue rebates and returns for the nine months ended September 30, 2026 and 2025:
Rebates, Returns and Other DeductionsContra AR AccrualsTotal
$$
Balance at December 31, 2025
398,533 79,126 477,659 
Accrual724,460 788,511 1,512,971 
Payments(561,342)(776,155)(1,337,497)
Balance at September 30, 2026
561,651 91,482 653,133 
Balance at December 31, 2024
235,600 50,699 286,299 
Accrual457,909 565,065 1,022,974 
Payments(310,732)(564,676)(875,408)
Balance at September 30, 2025
382,777 51,088 433,865